RxDoctor Payments Data

Ankur Doshi, MD

Internal Medicine · Houston, TXNPI 1659487650

Payments from drug & device makers

$2,048,745in general payments, 2019–2025

Across 2,398 payments — averaging $854.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$622K
  • Novartis$334K
  • Pfizer$278K
  • Eli Lilly$249K
  • Janssen Research & Development, LLC$147K
  • Boehringer Ingelheim$82K
  • plus $336K from 49 others
$3,742in research payments, 2019–2025

Across 28 payments — averaging $133.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K
  • Gilead$1K
  • AbbVie$1K

What the payments were for

  • Consulting fees$9,53540%
  • Travel & lodging$6,62228%
  • Food & beverage$7,28431%
  • Education$1391%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS1,789$622,249
Novartis26$334,497
Pfizer105$277,703
Eli Lilly10$249,029
Janssen Research & Development, LLC35$146,945
Boehringer Ingelheim7$82,033
AbbVie(2 entities)65$70,355
Alnylam Pharmaceuticals Inc.20$61,019
Bayer12$40,860
Gilead7$28,799
Ironwood Pharmaceuticals, Inc10$27,848
AstraZeneca9$24,626
Biohaven Pharmaceuticals, Inc.8$17,744
Vifor (international) Ltd.5$13,586
F. Hoffmann-la Roche AG5$11,750
Takeda Pharmaceuticals U.S.A., Inc.9$10,122
Novo Nordisk55$9,563
Roche Diagnostics Operations, Inc.4$7,254
Boehringer Ingelheim Pharma GmbH & Co.kg1$6,677
E.r. Squibb & Sons, L.L.C.2$1,593
Boehringer Ingelheim International GmbH11$840
Amarin Pharma, Inc.54$647
Abbott16$633
Johnson & Johnson(2 entities)9$449
Amgen24$352
Astellas Pharma US Inc16$339
Merck26$265
Teva Pharmaceuticals USA, Inc.9$154
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$111
Sanofi-aventis U.S. LLC5$80
Eisai Inc.3$57
Sanofi Pasteur Inc.2$54
Kowa Pharmaceuticals America, Inc.3$41
Dexcom, Inc.2$39
Baylis Medical Technologies Inc.1$36
Genentech USA, Inc.2$33
Mylan Specialty L.p.2$32
Myocardial Solutions, Inc.1$28
Relievant Medsystems, Inc.1$27
GSK2$25
Argon Medical Devices, Inc.1$24
Boston Scientific1$24
Arbor Pharmaceuticals, Inc.2$24
Redhill Biopharma Inc.1$20
Sunovion Pharmaceuticals Inc.2$19
Si-bone, Inc.1$19
Esperion Therapeutics, Inc.1$19
Lilly USA, LLC1$15
Amneal Pharmaceuticals LLC1$14
Aytu Biopharma, Inc.1$14
Biogen1$13
Optinose US, Inc.1$13
Nestle Healthcare Nutrition Inc.1$13
Seqirus USA Inc1$13
Shire North American Group Inc1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,048,745 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$32,378
Medicare patients
189
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$107,329
JardianceEmpagliflozin74$82,243
FarxigaDapagliflozin Propanediol28$40,955
TrulicityDulaglutide27$31,910
XareltoRivaroxaban16$23,620
Repatha SureclickEvolocumab18$16,777
TrintellixVortioxetine Hydrobromide16$14,620
VascepaIcosapent Ethyl13$8,193
Levothyroxine Sodium401$4,610
Dexlansoprazole DrDexlansoprazole15$4,248
SynthroidLevothyroxine Sodium58$3,934
Rosuvastatin Calcium334$3,264
Atorvastatin Calcium374$2,727
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,669
Amlodipine Besylate243$2,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$9,563$107,32972 claims
Boehringer IngelheimJardiance$82,033$82,24374 claims
AstraZenecaFarxiga$24,626$40,95528 claims
Lilly USA, LLCTrulicity$15$31,91027 claims
Johnson & JohnsonXarelto$449$23,62016 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$10,122$14,62016 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$4,610401 claims
AbbVieSynthroid$70,355$3,93458 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →